Critical Contrast: Nemaura Medical (NASDAQ:NMRD) Versus ICU Medical (NASDAQ:ICUI)
Critical Contrast: Nemaura Medical (NASDAQ:NMRD) Versus ICU Medical (NASDAQ:ICUI)
Nemaura Medical (NASDAQ:NMRD – Get Rating) and ICU Medical (NASDAQ:ICUI – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
纳斯达克：Nemaura Medical(代码：NMRD-GET Rating)和ICU Medical(纳斯达克：ICUI-GET Rating)都是医疗公司，但哪一家是优势投资？我们将根据这两家公司的风险、收益、分析师建议、股息、估值、盈利能力和机构持股的强弱对它们进行比较。
Earnings and Valuation
收益和估值
This table compares Nemaura Medical and ICU Medical's gross revenue, earnings per share and valuation.
此表比较了Nemaura Medical和ICU Medical的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nemaura Medical | $500,000.00 | 100.26 | -$13.89 million | ($0.62) | -3.35 |
| ICU Medical | $1.32 billion | 2.73 | $103.14 million | $0.42 | 358.58 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Nemaura医疗 | $500,000.00 | 100.26 | -1,389万元 | ($0.62) | -3.35 |
| ICU医疗 | 13.2亿美元 | 2.73 | 1.0314亿美元 | $0.42 | 358.58 |
ICU Medical has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.
ICU医疗的收入和收益高于Nemaura医疗。Nemaura Medical的市盈率低于ICU Medical，这表明它目前是两只股票中更负担得起的一只。
Insider & Institutional Ownership
内部人与机构所有权
Risk & Volatility
风险与波动性
Nemaura Medical has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Nemaura Medical的贝塔系数为-0.01，这意味着其股价的波动性比标准普尔500指数低101%。相比之下，ICU Medical的贝塔系数为0.57，这意味着其股价的波动性比标准普尔500指数低43%。
Analyst Recommendations
分析师建议
This is a breakdown of current recommendations for Nemaura Medical and ICU Medical, as reported by MarketBeat.
这是MarketBeat报道的Nemaura Medical和ICU Medical的当前建议的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nemaura Medical | 0 | 0 | 1 | 0 | 3.00 |
| ICU Medical | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Nemaura医疗 | 0 | 0 | 1 | 0 | 3.00 |
| ICU医疗 | 0 | 0 | 2 | 0 | 3.00 |
Nemaura Medical presently has a consensus price target of $8.00, indicating a potential upside of 284.62%. ICU Medical has a consensus price target of $207.50, indicating a potential upside of 37.78%. Given Nemaura Medical's higher probable upside, analysts plainly believe Nemaura Medical is more favorable than ICU Medical.
Nemaura Medical目前的共识目标价为8.00美元，表明潜在上涨284.62%。ICU Medical的共识目标价为207.50美元，表明潜在涨幅为37.78%。鉴于Nemaura Medical更有可能上行，分析师显然认为Nemaura Medical比ICU Medical更有利。
Profitability
盈利能力
This table compares Nemaura Medical and ICU Medical's net margins, return on equity and return on assets.
此表比较了Nemaura Medical和ICU Medical的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Nemaura Medical | N/A | -3,060.48% | -57.81% |
| ICU Medical | 0.31% | 6.97% | 3.99% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Nemaura医疗 | 不适用 | -3,060.48% | -57.81% |
| ICU医疗 | 0.31% | 6.97% | 3.99% |
Summary
摘要
ICU Medical beats Nemaura Medical on 10 of the 13 factors compared between the two stocks.
ICU Medical在两只股票比较的13个因素中有10个击败了Nemaura Medical。
About Nemaura Medical
Nemaura医疗公司简介
(Get Rating)
(获取评级)
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Nemaura Medical Inc.是一家医疗技术公司，负责发现、开发和商业化诊断医疗设备。它提供SugarBEAT，一种供I型和II型糖尿病患者使用的非侵入性连续血糖监测设备，以及筛查糖尿病前期患者。该公司还提供ProBEAT，一种健康指导笔记，提供提示并教育用户有关影响血糖曲线的因素，以及开展糖尿病预防和逆转计划。Nemaura Medical Inc.成立于2009年，总部设在纽约。
About ICU Medical
关于ICU医疗
(Get Rating)
(获取评级)
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
ICU医疗公司及其子公司在全球范围内开发、制造和销售用于输液治疗和危重护理应用的医疗设备。该公司的输液治疗产品包括MicroClave、MicroClave Clear和NanoClave品牌的无针产品；中子导管通畅设备；SwabCap和SwabTip消毒帽；Tego血液透析连接器；ClearGuard HD，血液透析导管的抗菌屏障帽；ChemoClave和ChemoLock封闭式系统传输设备，以及用于制备危险药物的Diana危险药物复合系统。它还提供静脉治疗和稀释剂，如氯化钠、葡萄糖、平衡电解质溶液、乳酸林格氏症、林格氏症、甘露醇、氯化钠/葡萄糖和无菌水；灌溉包括氯化钠和无菌水灌溉、生理溶液、林格氏灌溉、醋酸灌溉、甘氨酸灌溉、山梨醇-甘露醇灌溉、弹性容器和灌装瓶选项。该公司提供Plum 360和LifeCare PCA品牌的输液泵；IV中介安全软件，包括ICU Medical MedNet，这是一个企业级药物管理平台，将智能泵连接到医院的电子健康记录、资产跟踪系统和警报通知平台；以及相关专业服务。该公司还提供重症监护产品，如Cogent二合一和心脏Flo血流动力学监测系统；TDQ和OptiQ心输出量监测导管；TriOx静脉血氧仪导管；TRANSPAC血压传感器；以及SafeSet封闭式血液采样和保存系统。该公司将其产品销售给急性护理医院、批发商、门诊诊所和备用场所设施，包括门诊诊所、家庭保健提供者和长期护理设施。ICU医疗, 公司成立于1984年，总部设在加利福尼亚州圣克莱门特。
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nemaura医学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nemaura Medical和相关公司的最新新闻和分析师评级的每日简要摘要。